Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) dropped 4.6% during mid-day trading on Friday . The company traded as low as $8.28 and last traded at $8.30. Approximately 76,727 shares traded hands during trading, a decline of 80% from the average daily volume of 393,074 shares. The stock had previously closed at $8.70.
Wall Street Analyst Weigh In
Several brokerages have issued reports on BCYC. Morgan Stanley set a $17.00 price target on shares of Bicycle Therapeutics and gave the company an "equal weight" rating in a report on Monday, May 5th. HC Wainwright restated a "buy" rating and set a $33.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price target on shares of Bicycle Therapeutics in a research report on Friday, May 2nd. Barclays dropped their target price on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Finally, JMP Securities lowered their price objective on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a report on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.00.
Check Out Our Latest Analysis on BCYC
Bicycle Therapeutics Stock Performance
The company has a market capitalization of $569.27 million, a P/E ratio of -2.50 and a beta of 1.60. The business has a fifty day moving average of $7.98 and a 200-day moving average of $12.04.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $9.98 million for the quarter, compared to analysts' expectations of $8.67 million. Sell-side analysts anticipate that Bicycle Therapeutics plc will post -3.06 EPS for the current year.
Institutional Trading of Bicycle Therapeutics
A number of large investors have recently modified their holdings of BCYC. Barclays PLC lifted its position in Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock valued at $76,000 after purchasing an additional 8,065 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after acquiring an additional 2,191 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in Bicycle Therapeutics by 90.3% in the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after acquiring an additional 6,057 shares in the last quarter. Institutional investors own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Recommended Stories
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
